About this trial
The goal of this clinical trial is to learn if a multi-professional (conducted by geriatricians, clinical pharmacists, nurses) medication revision, centered on patients' goals and characteristics, can improve treatment adequacy in older adults admitted to an intermediate care hospital.
The main question it aims to answer is: does this approach reduce the average number of medications taken per patient?
Researchers will compare this multi-professional patient-centered revision to the usual standard of care (treatment revision conducted by a clinical pharmacist) to see if the patient-centered revision works in improving treatment adequacy.
Participants admitted to an intermediate care hospital will undergo a comprehensive assessment by a geriatrician, and a medication revision (conducted by a multidisciplinary team or a clinical-pharmacist alone). They will also be asked to fulfill some questionnaires on their health status and attitudes. Any possible adverse events to the medications will be recorded at discharge. Participants will be contacted again three months after discharge to check for any readmission or death.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
older adults (65+ years)
≥ 3 or more chronic conditions requiring medical therapy
able to speak Spanish
capacity to provide informed consent or have a surrogate able to consent on their behalf
Disqualifiers
unable to provide informed consent
anticipated length of hospital stay < 72h
estimated life expectancy < 3 months
homeless
Trial design
Parallel
Treatments tested in this trial
Patient-centered multidisciplinary treatment review
Other interventionPatient-centered multidisciplinary treatment review is defined as a medication review conducted by a multidisciplinary team (geriatrician, clinical pharmacist, nurse) according to a patient-centered methodology, based on person-centered evaluation of both personal and clinical insights, diagnostic-centered evaluation (based on current guidelines), and drug-centered evaluation (based on adequacy)
Treatment groups
Trial outcomes
Primary outcomes
Number of drugs
Median number of drugs per patient
Sponsors and contacts
Click on the lead sponsor to view all of their trials.